Sign In
Buy RVTY
$111.11
-1.18 (-1.05%)
At Close: Jul 13, 2026
Revvity to Hold Earnings Call on Tuesday, August 4, 2026
08:00am, Wednesday, 08'th Jul 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company
Revvity Expands Signals AI With Anthropic Claude Integration
11:01am, Thursday, 02'nd Jul 2026
RVTY expands Signals AI through Anthropic's MCP ecosystem, giving scientists secure Claude access to connected R&D data and scientific context.
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
08:00am, Wednesday, 01'st Jul 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling
Revvity Launches Signals AI to Advance Scientific R&D Workflows
09:50am, Tuesday, 23'rd Jun 2026
RVTY expands AI capabilities in Signals software with Signals AI, designed to help scientists turn connected R&D data into actionable insights.
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
08:00am, Monday, 22'nd Jun 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabili
Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
10:52am, Tuesday, 09'th Jun 2026
Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?
12:35pm, Thursday, 04'th Jun 2026
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
01:01pm, Thursday, 14'th May 2026
Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.
Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:10pm, Wednesday, 13'th May 2026
Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
08:00am, Wednesday, 13'th May 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution
11:41am, Tuesday, 05'th May 2026
Revvity beat Q1 EPS and revenue estimates as 3% organic growth and portfolio execution offset margin pressure and China ImmunoDx divest plans.
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
11:01am, Tuesday, 05'th May 2026
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics
10:30am, Tuesday, 05'th May 2026
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare t
Revvity (RVTY) Q1 Earnings and Revenues Top Estimates
08:45am, Tuesday, 05'th May 2026
Revvity (RVTY) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.01 per share a year ago.
Revvity Announces Financial Results for the First Quarter of 2026
06:00am, Tuesday, 05'th May 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing op
